NotableEligibility criteria expanded, about 14 wordsShow 6 more changesShow less
Trial completed
Final enrollment: 80 participants (planned 60)
Primary completion date changed from estimate of May 1, 2026 to Jun 26, 2026
Study completion date changed from estimate of May 31, 2026 to Sep 11, 2026
Secondary endpoints: details revised at 1 of 1 entry
Site details revised
Study First Submitted
Notable: the plan changed
Endpoints
Primary
VAS Level
Timeframe: 1st, 2nd, 4th, 8th, and 24th hours after extubation.
Secondary (1)
PONV
Arms and interventions
Group C (control group)No intervention
Patients in this group received a standard fentanyl infusion during the entire CABG procedure until they were transferred out of the operating room."
Group M (group morphine)Experimental
Patients in this group received 5 mg of morphine prior to the initiation of the surgical procedure and an additional 5 mg at the time of separation from cardiopulmonary bypass.
Drugs: In this study, morphine administration, which is routinely and frequently used in our operating room for patients undergoing CABG, was applied as an additional intervention
Sites
1 site in 1 country
Istanbul University -Cerrahpasa Institute of CardiologyIstanbul, Outside of the US, Turkey (Türkiye)